This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cordon-Cardo, C. Articles by Fradet, Y. Search for Related Content PubMed PubMed Citation Articles by Cordon-Cardo, C. Articles by Fradet, Y.

American Journal of Pathology, Vol 140, 375-385, Copyright © 1992 by American Society for Investigative Pathology

REGULAR ARTICLES

Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors

C Cordon-Cardo, DD Wartinger, MR Melamed, W Fair and Y Fradet
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

The authors have further characterized the normal human tissue distribution and tumor expression of two highly restricted tumor- associated antigens, detected by mouse monoclonal antibodies M344 and 19A211, which are primarily expressed on low-grade superficial urinary bladder tumors. This study was conducted using immunohistochemical staining of frozen and deparaffinized sections of human normal and tumor tissues. The antigens are stable and well preserved on deparaffinized tissue sections. M344 antibody identifies a high- molecular-weight determinant on a cytosolic protein component of over 300,000 Mr. This antigen was not detected on any normal tissue analyzed, including 14 specimens of normal urothelium and 22 cases of cystitis; however, M344 was positive in 74.5% of Ta-T1 tumors and 11% of T3-T4 tumors. 19A211 antibody identifies a sialylated epitope on a cytoplasmic protein complex of 100,000 to 200,000 Mr. This antigen also was expressed preferentially on low-grade superficial bladder tumors (77% Ta-T1) and less frequently on deeply infiltrating tumors (10% T3- 4). 19A211 was negative on all normal cells tested, with the exception of umbrella cells, in approximately 25% of the normal urothelium and cystitis specimens studied. Either one or both of these tumor- associated antigens are detected in approximately 80% of low-grade papillary superficial tumors and carcinoma in situ of the urinary bladder. The expression of these antigens on a subset of low-grade bladder tumors, known to progress in only about 10% of cases, suggests that phenotypic differences may reflect biologic potential. Beyond their possible biologic significance, antibodies M344 and 19A211 may provide clinically useful probes for early detection and stratification of urinary bladder tumors.

This article has been cited by other articles:

				A. Kumar, R. Kumar, and N. P. Gupta Comparison of NMP22 BladderChek Test and Urine Cytology for the Detection of Recurrent Bladder Cancer Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 172 - 175. [Abstract] [Full Text] [PDF]

				M. Sanchez-Carbayo, A. Espasa, V. Chinchilla, E. Herrero, J. Megias, A. Mira, and F. Soria New Electrochemiluminescent Immunoassay for the Determination of CYFRA 21-1: Analytical Evaluation and Clinical Diagnostic Performance in Urine Samples of Patients with Bladder Cancer Clin. Chem., November 1, 1999; 45(11): 1944 - 1953. [Abstract] [Full Text] [PDF]

				A. Bergeron, S. Champetier, Hélèn. LaRue, and Y. Fradet MAUB Is a New Mucin Antigen Associated with Bladder Cancer J. Biol. Chem., March 22, 1996; 271(12): 6933 - 6940. [Abstract] [Full Text] [PDF]